Mammalian Target of Rapamycin Activator RHEB is Frequently Overexpressed in Human Carcinomas and is Critical and Sufficient for Skin Epithelial Carcinogenesis

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Apr 15

PMID 20388784

Citations 48

Authors

Zhi Hong Lu

Mark B Shvartsman

Andrew Y Lee

Jenny M Shao

Mollianne M Murray

Raleigh D Kladney

Dong Fan

Stan Krajewski

Gary G Chiang

Gordon B Mills

Jeffrey M Arbeit

Affiliations

Soon will be listed here.

Abstract

Small GTPase Ras homologue enriched in brain (RHEB) binds and activates the key metabolic regulator mTORC1, which has an important role in cancer cells, but the role of RHEB in cancer pathogenesis has not been shown. By performing a meta-analysis of published cancer cytogenetic and transcriptome databases, we defined a gain of chromosome 7q36.1-q36.3 containing the RHEB locus, an overexpression of RHEB mRNA in several different carcinoma histotypes, and an association between RHEB upregulation and poor prognosis in breast and head and neck cancers. To model gain of function in epithelial malignancy, we targeted Rheb expression to murine basal keratinocytes of transgenic mice at levels similar to those that occur in human squamous cancer cell lines. Juvenile transgenic epidermis displayed constitutive mTORC1 pathway activation, elevated cyclin D1 protein, and diffuse skin hyperplasia. Skin tumors subsequently developed with concomitant stromal angio-inflammatory foci, evidencing induction of an epidermal hypoxia-inducible factor-1 transcriptional program, and paracrine feed-forward activation of the interleukin-6-signal transducer and activator of transcription 3 pathway. Rheb-induced tumor persistence and neoplastic molecular alterations were mTORC1 dependent. Rheb markedly sensitized transgenic epidermis to squamous carcinoma induction following a single dose of Ras-activating carcinogen 7,12-dimethylbenz(a)anthracene. Our findings offer direct evidence that RHEB facilitates multistage carcinogenesis through induction of multiple oncogenic mechanisms, perhaps contributing to the poor prognosis of patients with cancers overexpressing RHEB.

Citing Articles

Lomitapide repurposing for treatment of malignancies: A promising direction.

Wu H, Wu B, Fang Z, Wu Z, Hou Y, Deng Y Heliyon. 2024; 10(12):e32998.

PMID: 38988566 PMC: 11234027. DOI: 10.1016/j.heliyon.2024.e32998.

Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.

Ang D, Carter J, Deka K, Tan J, Zhou J, Chen Q Nat Commun. 2024; 15(1):2513.

PMID: 38514625 PMC: 10957915. DOI: 10.1038/s41467-024-46728-4.

Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling.

Rahman M, Nguyen T, Lee G, Kim B, Park M, Lee C Int J Mol Sci. 2024; 25(3).

PMID: 38338768 PMC: 10855792. DOI: 10.3390/ijms25031489.

Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer.

Mir S, Dar A, Alshehri S, Wahab S, Hamid L, Almoyad M Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513916 PMC: 10384750. DOI: 10.3390/ph16071004.

Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of Cells.

Armijo M, Escalona E, Pena D, Farias A, Morin V, Baumann M Front Pharmacol. 2022; 13:912688.

PMID: 35814251 PMC: 9260180. DOI: 10.3389/fphar.2022.912688.

References

Chung C, Parker J, Karaca G, Wu J, Funkhouser W, Moore D . Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5(5):489-500. DOI: 10.1016/s1535-6108(04)00112-6. View

Mavrakis K, Zhu H, Silva R, Mills J, Teruya-Feldstein J, Lowe S . Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 2008; 22(16):2178-88. PMC: 2518821. DOI: 10.1101/gad.1690808. View

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

Haar E, Lee S, Bandhakavi S, Griffin T, Kim D . Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007; 9(3):316-23. DOI: 10.1038/ncb1547. View

Podsypanina K, Lee R, Politis C, Hennessy I, Crane A, Puc J . An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A. 2001; 98(18):10320-5. PMC: 56959. DOI: 10.1073/pnas.171060098. View

Neshat M, Mellinghoff I, Tran C, Stiles B, Thomas G, Petersen R . Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001; 98(18):10314-9. PMC: 56958. DOI: 10.1073/pnas.171076798. View

Krajewska M, Zapata J, Meinhold-Heerlein I, Hedayat H, Monks A, Bettendorf H . Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002; 4(2):129-40. PMC: 1550319. DOI: 10.1038/sj.neo.7900222. View

Guertin D, Sabatini D . Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008. View

Robb V, Karbowniczek M, Klein-Szanto A, Henske E . Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2006; 177(1):346-52. DOI: 10.1016/j.juro.2006.08.076. View

10.

Fujishita T, Aoki K, Lane H, Aoki M, Taketo M . Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A. 2008; 105(36):13544-9. PMC: 2533226. DOI: 10.1073/pnas.0800041105. View

11.

Lee C, Inoki K, Guan K . mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2006; 47:443-67. DOI: 10.1146/annurev.pharmtox.47.120505.105359. View

12.

Wei C, Amos C, Zhang N, Wang X, Rashid A, Walker C . Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res. 2008; 14(4):1167-71. DOI: 10.1158/1078-0432.CCR-07-4007. View

13.

Johannessen C, Johnson B, Williams S, Chan A, Reczek E, Lynch R . TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008; 18(1):56-62. DOI: 10.1016/j.cub.2007.11.066. View

14.

Krajewska M, Smith L, Rong J, Huang X, Hyer M, Zeps N . Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem. 2009; 57(7):649-63. PMC: 2699321. DOI: 10.1369/jhc.2009.952812. View

15.

Rakha E, Ellis I . Triple-negative/basal-like breast cancer: review. Pathology. 2008; 41(1):40-7. DOI: 10.1080/00313020802563510. View

16.

Thomas G . mTOR and cancer: reason for dancing at the crossroads?. Curr Opin Genet Dev. 2005; 16(1):78-84. DOI: 10.1016/j.gde.2005.12.003. View

17.

Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T . gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15(2):91-102. DOI: 10.1016/j.ccr.2009.01.002. View

18.

Molinolo A, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A . Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res. 2007; 13(17):4964-73. DOI: 10.1158/1078-0432.CCR-07-1041. View

19.

Gwinn D, Shackelford D, Egan D, Mihaylova M, Mery A, Vasquez D . AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30(2):214-26. PMC: 2674027. DOI: 10.1016/j.molcel.2008.03.003. View

20.

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View